Kyverna Therapeutics, Inc. Stock Analysis & AI Score
Kyverna Therapeutics, Inc. (KYTX) has an ST Score of 39.9 (C), driven by its Forecast (A) and held back by its Profitability (D). Analysts rate it Buy with a $25.00 price target (+257.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Kyverna Therapeutics, Inc. (KYTX) has an ST Score of 39.9 (C), driven by its Forecast (A) and held back by its Profitability (D). Analysts rate it Buy with a $25.00 price target (+257.7% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityD
All factor grades
- ForecastA
- ValuationB
- Financial StrengthB-
- MomentumC-
- GrowthD+
- ProfitabilityD
- Piotroski1/9
Contact
KYTX stock: frequently asked questions
What is KYTX's ST Score?
Kyverna Therapeutics, Inc. (KYTX) has an ST Score of 39.9 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KYTX a buy, hold, or sell?
Analysts rate KYTX a Buy, with a price target of $25.00 (+257.7% vs the current price). Our ST Score grades it C (39.9/100). The ST Score is a data-driven signal, not a recommendation.
What are KYTX's factor grades?
Valuation B, Profitability D, Financial Strength B-, Momentum C-, Growth D+, Forecast A.
What is KYTX's valuation grade?
Kyverna Therapeutics, Inc. (KYTX) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KYTX's growth grade?
Kyverna Therapeutics, Inc. (KYTX) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KYTX's profitability grade?
Kyverna Therapeutics, Inc. (KYTX) earns a profitability grade of D, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KYTX's financial strength grade?
Kyverna Therapeutics, Inc. (KYTX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KYTX?
The average analyst price target for Kyverna Therapeutics, Inc. (KYTX) is $25.00 from 4 analysts, which is +257.7% versus the recent price of $6.99.
What is KYTX's Piotroski score?
Kyverna Therapeutics, Inc. (KYTX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.